LOSE WEIGHT WITH MEDICAL SUPPORT — BUILT FOR MEN
- Your personalised programme is built around medical care, not willpower.
- No generic diets. No guesswork.
- Just science-backed results and expert support.
Find out if you’re eligible
Mounjaro (tirzepatide) is a prescription medicine licensed in the UK for type 2 diabetes and weight management in adults with obesity or overweight with weight-related comorbidities. Many people wonder whether Mounjaro specifically burns belly fat. Whilst Mounjaro does not directly 'burn' fat tissue, clinical evidence shows it facilitates significant overall weight loss—including reductions in abdominal and visceral fat—primarily through appetite suppression and improved metabolic regulation. This article examines how Mounjaro works, the clinical evidence on body fat reduction, realistic outcomes, and safe prescribing guidelines in the UK.
Quick Answer: Mounjaro does not directly burn belly fat but facilitates significant overall weight loss, including reductions in abdominal and visceral fat, primarily through appetite suppression and improved metabolic regulation when combined with diet and exercise.
Mounjaro (tirzepatide) is a prescription medicine licensed in the UK for the treatment of type 2 diabetes mellitus and, more recently, for weight management in adults with obesity or overweight with weight-related comorbidities, as an adjunct to reduced-calorie diet and increased physical activity. It belongs to a novel class of medications known as dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists. This dual mechanism distinguishes Mounjaro from other GLP-1 receptor agonists such as semaglutide.
The medication works by mimicking two naturally occurring incretin hormones that regulate blood glucose and appetite. GLP-1 stimulates insulin secretion when blood glucose levels are elevated, suppresses glucagon release, slows gastric emptying, and reduces appetite through effects on the brain's satiety centres. GIP also enhances insulin secretion and may influence fat metabolism and energy expenditure, though these effects are not fully elucidated. Together, these actions help lower blood sugar levels in people with type 2 diabetes and promote weight loss by reducing hunger and caloric intake.
Mounjaro is administered as a once-weekly subcutaneous injection using a pre-filled pen device. Treatment begins with a 2.5 mg weekly dose for 4 weeks, intended for initiation only, before up-titration in 2.5 mg increments to a maintenance dose of 5-15 mg weekly, depending on individual response and tolerability. It is important to understand that Mounjaro is not a 'fat-burning' medication in the traditional sense—it does not directly metabolise or 'burn' fat tissue. Rather, it facilitates weight loss primarily through appetite suppression and improved metabolic regulation, which can lead to a reduction in overall body fat, including abdominal fat, when combined with appropriate lifestyle modifications.
Mounjaro is not indicated for type 1 diabetes or for the treatment of diabetic ketoacidosis.
Clinical trial data demonstrate that Mounjaro produces significant weight loss in both people with type 2 diabetes and those with obesity without diabetes. The SURMOUNT clinical trial programme evaluated tirzepatide specifically for weight management in adults with obesity or overweight. In the SURMOUNT-1 trial, participants without diabetes who received the highest dose (15 mg weekly) achieved an average weight loss of approximately 20.9% of their initial body weight over 72 weeks, compared to 3.1% in the placebo group. Those receiving lower doses (5 mg and 10 mg) lost an average of 15% and 19.5% respectively.
Regarding body composition, studies using imaging techniques such as dual-energy X-ray absorptiometry (DEXA) and MRI scans have shown that weight loss with tirzepatide includes reductions in both subcutaneous fat (fat beneath the skin) and visceral adipose tissue—the metabolically active fat stored around internal organs in the abdominal cavity. The SURPASS-3 MRI sub-study demonstrated significant reductions in visceral and hepatic fat. Visceral fat is particularly associated with increased cardiovascular and metabolic risk. While Mounjaro does not selectively target belly fat, the overall fat loss achieved includes significant reductions in abdominal adiposity.
It is worth noting that weight loss includes some reduction in lean body mass as well as fat mass. Maintaining adequate protein intake and incorporating resistance exercise may help preserve muscle mass during treatment.
It is crucial to note that there is no official evidence that Mounjaro 'burns' fat through direct lipolytic mechanisms. The reduction in body fat, including abdominal fat, occurs as a consequence of sustained caloric deficit achieved through appetite suppression, improved satiety, and metabolic improvements. The medication works best when combined with a reduced-calorie diet and increased physical activity, as recommended in clinical guidelines. Individual results vary considerably based on baseline weight, adherence to lifestyle modifications, dose, and duration of treatment.
LOSE WEIGHT WITH MEDICAL SUPPORT — BUILT FOR MEN
Find out if you’re eligible
Patients considering Mounjaro should have realistic expectations about the timeline and nature of weight loss. Weight reduction typically begins within the first few weeks of treatment, but significant changes in body composition, including noticeable reductions in abdominal circumference, generally occur over several months. Most clinical trials assessed outcomes at 52 to 72 weeks, with average weight loss of 15-21% at the highest doses, indicating that sustained treatment is necessary for optimal results.
Common experiences during treatment include:
Gradual weight loss: Most people experience greater losses in the first 3-6 months, with rates varying by dose and individual factors
Reduced appetite and portion sizes: Many patients report feeling fuller sooner and experiencing fewer food cravings
Gastrointestinal side effects: Nausea, diarrhoea, constipation, and abdominal discomfort are common, particularly during dose escalation. These typically improve over time
Changes in body measurements: Reductions in waist circumference often accompany weight loss, reflecting decreases in abdominal fat
It is important to understand that Mounjaro is not a quick fix or standalone solution. The medication is most effective when integrated into a comprehensive weight management programme that includes dietary modification, regular physical activity, and behavioural support. Weight loss may plateau after several months, and some weight regain can occur if the medication is discontinued without maintained lifestyle changes.
Patients should contact their GP or prescribing clinician if they experience:
Severe or persistent abdominal pain (which may indicate pancreatitis or gallbladder problems)
Right upper quadrant pain, especially with fever or jaundice (possible gallbladder disease)
Signs of dehydration due to vomiting or diarrhoea
Symptoms of hypoglycaemia if taking insulin or sulfonylureas (these medications may need dose reduction)
Unexplained visual changes or severe headaches (particularly in patients with diabetes, as rapid improvement in blood glucose can temporarily worsen diabetic retinopathy)
Signs of allergic reaction
Regular monitoring of weight, metabolic parameters, and tolerability is essential throughout treatment.
In the UK, Mounjaro is regulated by the Medicines and Healthcare products Regulatory Agency (MHRA) and prescribing guidance is provided by the National Institute for Health and Care Excellence (NICE). Tirzepatide is recommended by NICE for managing type 2 diabetes in specific circumstances, typically when other treatments have not achieved adequate glycaemic control. For weight management, NICE guidance is evolving, and availability through the NHS is typically limited to specialist weight management services for patients meeting specific criteria.
The licensed indication for weight management includes:
Body mass index (BMI) ≥30 kg/m², or ≥27 kg/m² with weight-related comorbidities (such as hypertension, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease)
Use as an adjunct to reduced-calorie diet and increased physical activity
However, NHS access may be more restrictive than the licensed indication, typically requiring assessment through specialist weight management services and meeting specific NICE criteria.
Important safety considerations include:
Mounjaro is not recommended during pregnancy or breastfeeding; effective contraception should be discussed with women of childbearing potential
The medication should be discontinued at least 1 month before a planned pregnancy
Tirzepatide can reduce the exposure to oral contraceptives; additional barrier or non-oral contraception is advised for 4 weeks after initiation and after each dose increase
Patients taking insulin or sulfonylureas may need dose reductions to prevent hypoglycaemia; close glucose monitoring is recommended
There is an increased risk of gallbladder disease (gallstones, cholecystitis); patients should report symptoms promptly
Dehydration from gastrointestinal side effects may affect kidney function; adequate fluid intake is important
The 2.5 mg dose is for treatment initiation only and not intended for maintenance therapy
Patients should be educated on proper injection technique, storage, and disposal of sharps
Cost considerations are significant—private prescriptions can be expensive, and NHS availability may be restricted
Patients should always discuss the potential benefits and risks of Mounjaro with their healthcare provider and ensure they are receiving treatment through legitimate, regulated channels. The medication should never be obtained from unregulated online sources due to safety concerns regarding counterfeit products.
If you experience any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or via the Yellow Card app.
Mounjaro reduces abdominal fat indirectly by suppressing appetite and slowing gastric emptying, leading to sustained caloric deficit and overall fat loss, including visceral and subcutaneous fat around the abdomen, when combined with diet and exercise.
Weight loss typically begins within the first few weeks of treatment, but significant reductions in body composition and abdominal circumference generally occur over several months, with optimal results seen at 52 to 72 weeks in clinical trials.
Mounjaro is licensed for weight management in the UK, but NHS access is typically restricted to specialist weight management services for patients meeting specific NICE criteria, including BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidities.
All medical content on this blog is created based on reputable, evidence-based sources and reviewed regularly for accuracy and relevance. While we strive to keep content up to date with the latest research and clinical guidelines, it is intended for general informational purposes only.
DisclaimerThis content is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional with any medical questions or concerns. Use of the information is at your own risk, and we are not responsible for any consequences resulting from its use.
